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Objectives The purpose of this study was to describe the prevalence and severity of coronary artery disease (CAD) in rela-
tion to prognosis in symptomatic patients without coronary artery calcification (CAC) undergoing coronary com-
puted tomography angiography (CCTA).
Background The frequency and clinical relevance of CAD in patients without CAC are unclear.
Methods We identified 10,037 symptomatic patients without CAD who underwent concomitant CCTA and CAC scor-
ing. CAD was assessed as 50%, 50%, and 70% stenosis. All-cause mortality and the composite end-
point of mortality, myocardial infarction, or late coronary revascularization (90 days after CCTA) were
assessed.
Results Mean age was 57 years, 56% were men, and 51% had a CAC score of 0. Among patients with a CAC score of 0,
84% had no CAD, 13% had nonobstructive stenosis, and 3.5% had 50% stenosis (1.4% had 70% stenosis)
on CCTA. A CAC score 0 had a sensitivity, specificity, and negative and positive predictive values for stenosis
50% of 89%, 59%, 96%, and 29%, respectively. During a median of 2.1 years, there was no difference in
mortality among patients with a CAC score of 0 irrespective of obstructive CAD. Among 8,907 patients with
follow-up for the composite endpoint, 3.9% with a CAC score of 0 and 50% stenosis experienced an event
(hazard ratio: 5.7; 95% confidence interval: 2.5 to 13.1; p  0.001) compared with 0.8% of patients with a
CAC score of 0 and no obstructive CAD. Receiver-operator characteristic curve analysis demonstrated that
the CAC score did not add incremental prognostic information compared with CAD extent on CCTA for the
composite endpoint (CCTA area under the curve  0.825; CAC  CCTA area under the curve  0.826; p 
0.84).
Conclusions In symptomatic patients with a CAC score of 0, obstructive CAD is possible and is associated with increased car-
diovascular events. CAC scoring did not add incremental prognostic information to CCTA. (J Am Coll Cardiol
2011;58:2533–40) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.851
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scoring, using noncontrast com-
puted tomography, is a clinically
useful noninvasive estimate of cor-
onary artery disease (CAD) bur-
den (1). Among asymptomatic pa-
tients, the absence of measurable
CAC is associated with very low
adverse event rates (2), and CAC
scoring is endorsed as a screening
test in selected individuals (3)
based on a convincing body of
literature demonstrating that it
more precisely predicts adverse cardiovascular events compared
with standard cardiovascular risk factor scoring (4). In symp-
tomatic patients, absent CAC has been shown in several
studies to have a high sensitivity and negative predictive value
for excluding obstructive CAD (5), prompting a recent Amer-
ican College of Cardiology/American Heart Association con-
sensus statement to endorse CAC as a “filter” for invasive
angiography and/or hospital admission in patients with symp-
toms atypical for coronary ischemia (6). Specifically, it is
recommended that CAC scoring may be used in a binary
fashion (CAC present or absent) such that those without CAC
may avoid further evaluation for obstructive CAD. Similarly,
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accepted October 4, 2011.recent guidelines have broadly endorsed the use of CAC
scoring in selected symptomatic patients (7).
Several recent studies have questioned the utility of this
approach, demonstrating relatively high rates of obstructive
CAD in patients with CAC scores of 0, especially among
patients at high pre-test risk of obstructive CAD (8–13).
The prevalence of obstructive CAD among patients with
CAC scores of 0 who are at lower clinical risk of obstructive
CAD, such as those referred for coronary computed tomog-
raphy angiography (CCTA), has not been well studied.
Additionally, the prognostic importance of obstructive
CAD among patients with a CAC score of 0 and the
incremental prognostic value of CAC scoring performed at
the time of CCTA are unclear. The aim of the current study
was to assess the prevalence and extent of CAD and clinical
outcomes among a large, international registry cohort of
symptomatic patients without known coronary heart disease
who were referred for CCTA and found to have no
measurable CAC on pre-CCTA calcium scoring. The
incremental prognostic value of CAC scoring at the time of
CCTA was also explored.
Methods
Patients. The CONFIRM (Coronary CT Angiography
Evaluation for Clinical Outcomes: An International Mul-
ticenter) registry is an international, multicenter, observa-
tional registry collecting clinical, procedural, and follow-up
data on patients who underwent 64-detector row CCTA
between 2005 and 2009 at 12 centers in 6 countries
(Canada, Germany, Italy, Korea, Switzerland, and the
United States). The rationale, design, site-specific patient
characteristics, and follow-up durations have been described
(14). Symptomatic patients who underwent concomitant
CAC scoring and CCTA were included in the present
analysis. Individuals with known CAD (previous myocardial
infarction [MI] and/or coronary revascularization) were
excluded. Institutional review board approval was obtained
at each center.
As previously described (14), we prospectively collected
information on the presence of cardiovascular risk factors in
each individual. Chest pain was classified according to the
methods of Diamond and Forrester (15). CAC was quan-
tified according to the Agatston method (16).
Patient preparation, CCTA data acquisition, and clinical
result reporting were done according to Society of Cardio-
vascular Computed Tomography guidelines (17). Image
interpretation was performed in a uniform fashion at each
site according to Society of Cardiovascular Computed
Tomography guidelines (18) by highly experienced imagers
who were level III equivalent and/or board certified in
cardiovascular computed tomography. Coronary atheroscle-
rotic lesions were quantified for lumen diameter stenosis by
visual estimation and graded as none (0% luminal stenosis),
mild (1% to 49%), moderate (50% to 69%), or severe
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were defined as obstructive.
Follow-up and outcomes. The primary clinical endpoint
was time to death of any cause among patients from all 12
CONFIRM sites. In patients with complete follow-up for
MI and coronary revascularization, a secondary analysis was
performed assessing time to a composite endpoint consist-
ing of all-cause mortality, nonfatal MI, and coronary revas-
cularizations performed 90 days after CCTA. Coronary
revascularizations 90 days after CCTA were defined as
late, given our group’s previous demonstration that early
revascularizations are generally invoked by scan findings,
whereas late revascularizations are generally associated with
disease worsening (19). Early revascularizations (90 days
from CCTA) were reported separately as an outcome of
clinical interest.
Statistical analysis. Categorical variables are presented as
frequencies with percentages and evaluated using the chi-
square test. Continuous variables are presented as mean 1
SD or median (interquartile range) and were evaluated using
a Student unpaired t test or a Mann-Whitney U test, as
appropriate. Cumulative event-free survival was assessed
using the Kaplan-Meier method and compared with the log
rank test. Multivariable analyses were calculated with the
Baseline Characteristics and CCTA ResultsStratified According o the Detection of CAC(N  10,037)
Table 1
B seline Characteris ics and C TA Results
Stratified According to the Detection of CAC
(N  10,037)
CAC Score  0
(n  5,128)
CAC Score >0
(n  4,909) p Value
Age, yrs 52 12 61 11 0.001
Male 43 56 0.001
Hypertension 44 59 0.001
Diabetes 9 18 0.001
Hypercholesterolemia 51 62 0.001
Smoking 16 18 0.718
Family history of premature
CAD
29 33 0.001
Pre-test probability of
obstructive CAD*
32% (42) 54% (49) 0.001
Typical angina 13 16 0.001
Dyspnea 26 37 0.001
CAC score 0 (0) 90 (278) 0.001
CCTA results: worst stenosis
Normal coronaries 84 19 0.001
Nonobstructive (1%–49%) 13 52 0.001
Obstructive (50%) 3.5 29 0.001
Obstructive, severe (70%) 1.4 16 0.001
CCTA: no. of vessels with 50%
stenosis
1 2.8 17 0.001
2 0.4 8 0.001
3 0.2 3.3 0.001
Left main 0.3 1.6 0.001
Values are mean  SD, %, or median (interquartile range). *Defined according to the method of
iamond-Forrester.
CAC coronary artery calcification; CAD coronary artery disease; CCTA coronary computed
tomography angiography.Cox proportional hazard model (with 95% confidenceintervals), adjusted for differences in symptoms and clinical
cardiovascular risk factors. Variables associated with the
presence of obstructive CAD were assessed using univari-
able and multivariable logistic regression. To assess for
potential site-specific differences that may have limited
pooling of data and outcomes, we included site as a covariate
in each univariable and multivariable model and demon-
strated that there was no significant change in any of the
results. In addition, a series of interaction tests were per-
formed by site demonstrating no significant influence of
potential site-specific differences. To assess the incremental
prognostic value of calcium score and CCTA with respect
to baseline risk factors, Cox models were compared using
clinical risk factors for obstructive CAD calculated as the
Morise score (20), the Morise score plus CAC score
(categorized as zero calcium, 100, 101 to 400, and 400),
Morise score plus CCTA (categorized as no disease, 50%
orst stenosis, 1-vessel obstructive disease, 2- or 3-vessel/
eft main CAD), and Morise score plus CCTA and CAC.
eceiver-operator characteristic curves were prepared for
ach of the models and compared using the Delong
ethod (21). Statistical significance was accepted for
-sided p values 0.05. All calculations were performed
sing STATA version 11.0 (StataCorp, College Station,
exas).
esults
he CONFIRM registry, consisting of 27,125 patients, was
creened and 10,037 symptomatic patients without known
AD who underwent both CAC scoring and CCTA were
dentified. The mean age of patients in the cohort was 57
Figure 1 Coronary Artery Stenosis on CCTA
Increasing frequency of obstructive disease with increasing coronary artery cal-
cification (CAC) (Agatston) scores is demonstrated. *p  0.001 between
groups. CCTA  coronary computed tomography angiography.
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characteristics and CCTA results are shown in Table 1,
stratified according to the presence or absence of detectable
CAC on pre-CCTA calcium scanning. Among the 10,037
patients included in this analysis, 51% (n  5,128) had a
AC score of 0. Patients with a CAC score of 0 were
ounger and more likely female and had a lower burden of
ardiovascular risk factors compared with subjects with
etectable CAC (CAC score 0).
Patients with increasing degrees of CAC had significantly
ncreased severity of angiographic CAD on CCTA (Fig. 1).
n patients with a CAC score of 0, 16% of patients had
vidence of some degree of CAD on CCTA, with 13% of
atients with a CAC score of 0 having nonobstructive CAD
Figure 2 All-Cause Mortality-Free Survival
Survival among all patients according to worst coronary artery stenosis on coro-
nary computed tomography angiography demonstrating decreased survival
among patients with at least 1 major epicardial vessel with 50% stenosis.
CAD  coronary artery disease.
Univariable and Adjusted Multivariable PredictoStenosis on CCTA Among Patients With a CACTable 2 Univariabl and Adjusted MultivariaStenosis on CCTA Among Patients
Univariab
OR 95%
Age* 1.05 1.04–
Male* 1.36 1.01–
Body mass index 1.04 1.01–
Hypercholesterolemia 1.46 1.08–
Diabetes 2.51 1.72–
Family history of premature CAD* 2.35 1.74–
Hypertension 1.15 0.85–
Smoking* 1.45 1.00–
Chest pain
Nonanginal 1.05 0.67–
Atypical 0.84 0.60–
Typical 1.26 0.83–
Dyspnea* 1.80 1.27–
*Variables significantly predictive of 50% stenosis on CCTA in the a
CI  confidence interval; OR  odds ratio; other abbreviations as in(50% stenosis). The prevalence of any major epicardial
vessel with 50% and 70% stenosis on CCTA among
patients with a CAC score of 0 was 3.5% and 1.4%,
respectively. The majority of patients with a CAC score of
0 and obstructive CAD (n  180) had single-vessel disease
(82%), with a lower prevalence of 2-vessel (12%), 3-vessel
(6%), and left main (0.3%) disease. Using a 15-segment
coronary artery tree model, patients with a CAC score of 0,
and evidence of any CAD, the median number of segments
exhibiting any degree of plaque in patients with a CAC
score of 0 was 2 (interquartile range, 2).
For the detection of any stenosis 50% on CCTA, the
presence of measurable CAC (CAC score 0) on calcium
Figure 3 Survival According to CAC Score and Stenosis
Severity
All-cause mortality-free survival among patients according to CAC score and the
severity of coronary artery disease on coronary CCTA. Abbreviations as in Fig-
ure 1.
the Presence of >50% Coronaryof 0 (n  4,738)redictors of the Presence f >50% Coronary
a CAC Score of 0 (n  4,738)
ude) Multivariable (Adjusted)*
p Value OR 95% CI p Value
0.001 1.05 1.04–1.07 0.001
0.045 1.93 1.33–2.78 0.001
0.004 1.02 0.99–1.06 0.14
0.014 1.13 0.79–1.61 0.51
0.001 1.58 0.97–2.57 0.068
0.001 2.31 1.60–3.30 0.001
0.35
0.47 1.72 1.12–2.64 0.013
0.84
0.32
0.27
0.001 1.57 1.08–2.27 0.017
logistic regression model.
1.rs ofSc reble P
With
le (Cr
CI
1.06
1.82
1.06
1.98
3.66
3.18
1.55
2.09
1.63
1.18
1.90
2.56
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December 6, 2011:2533–40 Stenosis and Events in Calcium Scores of Zeroscoring demonstrated a sensitivity of 89%, specificity of
59%, negative predictive value of 96%, and positive predic-
tive value of 29%. When using a threshold of70% stenosis
for obstructive CAD, a CAC score 0 demonstrated a
sensitivity, specificity, negative predictive value and positive
predictive value of 92%, 55%, 99%, and 16%, respectively.
The positive likelihood ratio (LR) for a CAC score 0 to
predict 50% stenosis was 2.14; the negative LR was 0.19.
The positive LR for a CAC score 0 to predict a 70%
stenosis was 2.04; the negative LR was 0.15. In receiver-
operator characteristic analysis, the presence of any CAC
(compared with a CAC score of 0) significantly increased
the area under the curve (for the prediction of detecting a
stenosis from 0.74 to 0.82 (p  0.01).
Univariable and multivariable predictors of obstructive
CAD on CCTA among patients with a CAC score of 0
are shown in Table 2. After multivariable risk adjust-
ment, obstructive CAD in these patients was associated
with the traditional cardiovascular risk factors of increas-
ing age, male sex, and smoking. The strongest indepen-
dent predictors of obstructive CAD among patients
without CAC were a family history of premature CAD
among a first-degree relative and smoking. Typicality of
Figure 4 Survival Among Patients With a CAC Score of 0
Decreased event-free survival from major adverse events (all-mortality, nonfatal
myocardial infarction, or coronary revascularization) among patients without detect-
able CAC but 50% stenosis on coronary computed tomography angiography.
Abbreviations as in Figures 1 and 2.
Early* Revascularization Rates Among Patients With and WithoutTable 3 Early* Revascularization Rates Among Patients With a
CAC score 0 (n 4,738) No CAD (n 3,915) 50% stenosis (n
Early revascularization 0.1 (4) 0.77 (5)
CAC score 0 (n 4,169) No CAD (n 826) 50% stenosis (n
Early revascularization 1.2 (10) 0.97 (21)
p Value (CAC score: 0 vs. 0) 0.001 0.65
Values are % (n). *Occurring 90 d after CCTA.
Abbreviations as in Table 1.angina pectoris did not discriminate individuals with a
CAC score of 0 who did versus did not have obstructive
CAD, but dyspnea as a presenting symptom was highly
associated with the presence of obstructive CAD on
CCTA (adjusted odds ratio: 1.57; 95% confidence inter-
val: 1.08 to 2.27; p  0.017).
Mortality and adverse events. Among the entire cohort
(n  10,037), during a median follow-up of 2.1 (interquar-
tile range, 2.0) years, patients with any obstructive CAD by
CCTA experienced a significantly increased rate of all-cause
mortality (Fig. 2). When restricted to individuals with a
CAC score of 0, there was no difference in all-cause
mortality despite the presence of nonobstructive or obstruc-
tive CAD (Fig. 3).
Among the 8,907 patients with complete follow-up for
the secondary endpoints of coronary revascularization and
MI, patients with evidence of obstructive CAD had signif-
icantly increased rates of early coronary revascularization,
both among patients with and without coronary artery
calcification (Table 3).
Figure 5 Major Adverse Events Stratified by
CAC Score and Stenosis
Major adverse events stratified by the presence (pos) or absence (zero) of CAC
and 50% stenosis on CCTA. MI  myocardial infarction; Revasc  revasculariza-
tion; other abbreviations as in Figures 1 and 2.
Stratified by Stenosis Severity on CCTAithout CAC Stratified by Stenosis Severity on CCTA
CCTA Results
50% stenosis (n 177) 70% stenosis (n 67) p Value
22 (39) 34 (23) 0.001
6) 50% stenosis (n 1,187) 70% stenosis (n 638) p Value
29 (342) 44 (278) 0.001
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MI, or late coronary revascularization, significantly higher
rates of major adverse events were observed for patients with
a CAC score of 0 and obstructive CAD on CCTA
compared with patients with a CAC score of 0 and no or
nonobstructive CAD (Fig. 4). Specifically, during follow-
up, 3.9% (7 of 177) of patients with a CAC score of 0 and
50% stenosis experienced an adverse event compared with
0.8% of patients with a CAC score of 0 and no obstructive
CAD (p  0.001). After multivariable adjustment, the
resence of obstructive CAD conferred an increased hazard
atio for a combined adverse event by 5.7 (95% confidence
nterval: 2.5 to 13.1; p  0.001). This difference was
rimarily driven by an increase in late coronary revascular-
zations (5 of 7 events) (Fig. 5, Table 4).
Adverse Events Among Patients From 8 Sites With Composite EndDuring a M dian Follow-up of 2.1 YearsTable 4 Adverse Events Among Patien s From 8 Sites With CoDuring a Median Follow-up of 2.1 Years
Combined M
CAC score of 0 (n 4,738) 0.9 (44)
No CAD (n 3,915) 0.6 (24)
50% stenosis (n 646) 2.0 (13)
50% stenosis (n 177) 3.9 (7)
p Value (within a CAC score of 0 for increasing CAD) 0.001
CAC score 0 (n 4,169) 4.8 (191
No CAD (n 826) 0.4 (3)
50% stenosis (n 2,156) 2.5 (54)
50% stenosis (n 1,187) 11.3 (134
p Value (within a CAC score 0 for increasing CAD) 0.001
Values are % (n). *p  0.05 compared with patients with a CAC score of 0.
MAE  major adverse events (all-cause mortality, nonfatal MI, or coronary revascularization oc
Hazard Ratios for the Composite Outcome of AlL te Rev scularization According to Morise RisTable 5 H zard Ratios f r he Compo ite OuLate Revascularization According to
Variable (N  8,907)
Unadj
HR 9
Morise risk category
Low (1–8) 1.00
Intermediate (9–15) 3.71 1.7
High (16–24) 6.32 2.9
CAC score model
0 1.00
1–100 3.08 2.0
101–400 9.39 6.4
400 13.90 9.5
CCTA models
Presence of 50% CAD
None or 50% CAD 1.00
50% CAD 8.47 6.7
No. of involved vessels
None (no CAD) 1.00
50% stenosis 5.48 3.6
1-vessel disease (50% stenosis) 16.90 11
2-vessel disease 26.50 17
3-vessel and/or left main disease 32.50 20HR  hazard ratio; other abbreviations as in Tables 1, 2, and 4.omparative prognostic value of clinical variables, CAC
coring and CCTA. Hazard ratios, unadjusted and ad-
usted for Morise risk score categories, for the composite
utcome of all-cause mortality, nonfatal MI, and late
oronary revascularization are shown in Table 5. Increasing
AC scores, the presence of nonobstructive CAD, any
tenosis 50%, and the number of coronary territories with
50% stenosis were independently predictive of adverse
vents. Receiver-operator characteristic curves to determine
he predictive value of clinical risk factors (Morise score: model
); Morise score  CAC scoring (model 2); Morise score 
CTA (number of vessels with obstructive disease: model 3);
nd Morise score  CAC  CCTA (model 4) were directly
ompared. The addition of CAC scoring and the presence and
everity of CAD on CCTA each incrementally improved the
Assessment for MAEite Endpoint Assessment for MAE
Death MI Late Revascularization
0.4 (21) 0.2 (9) 0.34 (16)
0.5 (18) 0.1 (4) 0.05 (2)
0.5 (3) 0.5 (3) 1.4 (9)
0% (0) 1.1 (2) 2.8 (5)
0.7 0.002 0.001
1.8 (74) 1.1 (46) 2.2 (91)
0.2 (2) 0 (0) 0.1 (1)
1.5 (33) 0.5 (11) 0.7 (16)
3.3 (39) 3.0 (35) 6.2 (74)
0.001 0.001 0.001
90 days after testing); MI  myocardial infarction; other abbreviations as in Table 1.
se Mortality, Nonfatal MI, andr , CAC Score, and CCTAof ll-Caus Mor lity, Nonfatal MI, and
ise Risk Score, CAC Score, and CCTA
Model Risk Factor-Adjusted Model
p Value HR 95% CI p Value
7 0.001
5 0.001
1.00
8 0.001 2.82 1.83–4.35 0.001
7 0.001 7.16 4.66–11.0 0.001
4 0.001 9.78 6.29–15.2 0.001
1.00
7 0.001 7.10 5.40–9.33 0.001
1.00
8 0.001 4.19 2.63–6.68 0.001
4 0.001 13.50 8.52–21.4 0.001
5 0.001 20.70 12.6–33.9 0.001
2 0.001 27.10 16.0–45.9 0.001pointmpos
AE
)*
)*l-Cauk Scotcom
Mor
usted
5% CI
3–7.9
7–13.
7–4.5
2–13.
2–20.
0–10.
3–8.2
.2–25.
.0–41.
.2–52.
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December 6, 2011:2533–40 Stenosis and Events in Calcium Scores of Zeroability to predict future adverse events beyond clinical risk
factors alone. The number of vessels with obstructive CAD
(model 3) was superior to CAC scoring (model 2) for the
prediction of major adverse events (Fig. 6). CAC scoring
performed at the time of CCTA resulted in no incremental
improvement in predicting composite adverse events compared
with clinical risk factors and CCTA alone (model 3 vs. model 4,
p  0.84).
Discussion
In this large, multicenter, international cohort without known
CAD, clinically referred for noninvasive coronary angiography,
the absence of measurable CAC significantly reduced, but did
not fully exclude, the presence of obstructive CAD on current
generation CCTA. CAC scoring has been advocated as a
quick, noninvasive, iodinated contrast-free method to assess for
the likelihood of obstructive CAD in symptomatic patients
(6,7) based on studies demonstrating very low rates of obstruc-
tive disease in patients with a CAC score of 0 (5). However,
recent studies have shown significantly higher rates of obstruc-
tive CAD in patients with a CAC score of 0, ranging from 7%
to 38% of patients (8–13), especially when studied in patients
with higher risk presentations, consistent with Bayesian rea-
soning. The prevalence of significant CAD in patients with a
Figure 6 Receiver-Operator Characteristic Curves:
Major Adverse Events
Receiver-operator characteristic curves of 4 models for predicting composite major
adverse events in 8,907 patients over a median of 2.1 years. CAC score catego-
ries were defined as: 0, 100, 101 to 400, and 400. Model 2 (Morise score 
CAC category) compared to Model 1 (Morise score only): p  0.001. Model 3
(Morise score  number vessels 50% stenosis) compared to Model 2 (Morise
score  CAC category): p  0.001. Model 4 (Morise score  CAC category 
number vessels 50% stenosis) compared to Model 2 (Morise score  CAC cate-
gory): p  0.001. Model 3 compared to Model 4: p  0.84. AUC  area under
the curve; CAC  coronary artery calcification; CI  confidence interval.CAC score of 0 primarily at intermediate pre-test risk in thecurrent study was lower than many of these recent reports,
reaffirming the importance of properly assessing patient pre-
test probability for obstructive CAD if CAC scoring were to be
used in symptomatic patients, as endorsed by current expert
statements and guidelines (6,7).
The finding of increased rates of late coronary revascu-
larizations among patients with a CAC score of 0 and
50% stenosis on CCTA but no difference in mortality is
not surprising. The majority of patients with a CAC score
of 0 and obstructive disease had single-vessel disease, a
cohort in which coronary revascularization has not been
shown to improve survival. Also, due to the low-
intermediate risk population studied in this analysis, longer
term follow-up durations may be needed to fully assess the
prognostic value of nonobstructive CAD, and the potential
impact of preventive therapies (e.g., statins).
Viewed positively, CAC scoring (CAC score of 0)
significantly reduced the likelihood of finding significant
CAD on CCTA. However, CAC scoring as an initial
diagnostic test, applied in a binary fashion in which a CAC
score of 0 results in no further testing and a CAC score 0
is followed by additional testing, would have resulted in
3.5% of patients without an appropriate initial diagnosis of
obstructive CAD who are at increased risk of intermediate-
term adverse events and a large percentage of patients (those
with a CAC score 0) requiring further testing. The
performance of CAC scoring at the time of CCTA,
although often done to assist in CCTA scan acquisition
planning (e.g., identification of dense calcification that may
change scan acquisition parameters), did not add incremen-
tal prognostic value beyond clinical data and disease severity
by CCTA.
Study limitations. The definition of CAD was made using
CCTA and not invasive coronary angiography; therefore,
the possibility of false-positive and false-negative CCTA
findings exists despite the performance of CCTA by inter-
national experts. We also recognize that patients diagnosed
with obstructive CAD on CCTA are more likely to undergo
revascularization, especially early after testing. We at-
tempted to control for this by censoring early revasculariza-
tions from the composite endpoint. Differences in the
application of medical therapies after CCTA were not
assessed and may have affected patient outcomes. Finally,
we did not assess individual coronary plaque characteristics,
such as the degree of vessel remodeling, which may improve
the prognostic yield of CCTA (22).
Conclusions
In symptomatic patients referred for CCTA, the absence of
CAC reduces but does not fully eliminate the occurrence of
obstructive CAD. Among patients without CAC, the presence
of at least 1 coronary artery stenosis 50% is predictive of
increased rates of late coronary revascularizations and nonfatal
MIs during an intermediate-term follow-up period. CAC
scoring performed at the time of CCTA in an intermediate-
2540 Villines et al. JACC Vol. 58, No. 24, 2011
Stenosis and Events in Calcium Scores of Zero December 6, 2011:2533–40risk population does not appear to offer significant incremental
prognostic information when combined with clinical risk
factors and CAD severity on CCTA.
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